The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning about ...

Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of multiple sclerosis drugs including Teva's Copaxone. The health ...

Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information. Marketed under the ...

The US Food and Drug Administration (FDA) has added a boxed warning to the label of multiple sclerosis drug glatiramer acetate about the risk of anaphylaxis. From December 1996 through May 2024 ...

The following is a summary of “Cost–consequence analysis of early vs. delayed natalizumab use in highly active ...

The US agency maintains that Glatiramer acetate is an approved medicine to treat patients with relapsing forms of MS. (Image Credits: Reuters) The U.S. Food and Drug Administration (FDA ...

Please provide your email address to receive an email when new articles are posted on . The FDA has advised health care professionals and patients with multiple sclerosis that treatment with ...

*p = 0.03 for SC IFNβ-1b versus IM IFNβ-1a. **p < 0.001 for both doses of oral fingolimod versus IM IFNβ-1a. † Median. ‡ ARR over 48 weeks; difference not significant at this time point.

The drug, glatiramer acetate, is approved to treat patients with relapsing forms of multiple sclerosis, a chronic disease that affects the central nervous system. Teva markets the drug under the ...

The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment. Anaphylaxis symptoms can appear within an hour of injection and may lead to ...